Safety of Cannabidiol Given to Subject With Methadone or Buprenorphine
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The overarching goal of this study is to evaluate the potential of Cannabidiol (CBD) as an
adjunctive treatment for comorbid opioid use disorder (OUD) and chronic pain. This is a
randomized, placebo-controlled, crossover human laboratory study investigating the
dose-dependent safety and acute effects of CBD on measures of pain and opioid craving in
outpatients with OUD receiving medication-assisted treatment (MAT) with methadone or
buprenorphine.